Log-rank statistics to test the equality of the survival distributions for the different categoric variables in 39 cases of gastric DLBCL and DLCLML
Variable . | n . | P . |
|---|---|---|
| Translocation vs no translocation cases | 15 vs 24 | .333 |
| Ig/BCL6 vs non-Ig/BCL6 translocation cases | 10 vs 5 | .360 |
| Deregulating mutation vs no deregulating mutation cases | 8 vs 31 | .784 |
| Translocation/deregulating mutation vs no translocation/deregulating mutation cases | 22 vs 17 | .315 |
| Ongoing BCL6 somatic mutations in MMC [GCB] vs acquired but not active ongoing BCL6 somatic mutations in MMC [post-GCB] cases | 6 vs 16 | .734 |
| High BCL6 expression vs low BCL6 expression cases* | 26 vs 12 | .016 |
Variable . | n . | P . |
|---|---|---|
| Translocation vs no translocation cases | 15 vs 24 | .333 |
| Ig/BCL6 vs non-Ig/BCL6 translocation cases | 10 vs 5 | .360 |
| Deregulating mutation vs no deregulating mutation cases | 8 vs 31 | .784 |
| Translocation/deregulating mutation vs no translocation/deregulating mutation cases | 22 vs 17 | .315 |
| Ongoing BCL6 somatic mutations in MMC [GCB] vs acquired but not active ongoing BCL6 somatic mutations in MMC [post-GCB] cases | 6 vs 16 | .734 |
| High BCL6 expression vs low BCL6 expression cases* | 26 vs 12 | .016 |
MMC indicates major mutation cluster located at 5′ of the first intron.
BCL6 protein expression was assessed by a 4-point system based on the proportion of positive cells with nuclear staining and was scored as low (- and +) or high (++ and +++). BCL6 expression could not be studied in 1 case due to the unavailability of paraffin block for the case.